Parkinson hastalığında sialorrhea tedavisinde dihidroergotoksin mesilatın orta-uzun süreli etkinliği.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

PurposeTo further assess the mid-long term effects of dihydroergotoxine mesylate (DHM) on salivation in patients with Parkinson's disease (PD).MethodsThirty-nine participants were enrolled in a 24-week, open, self-controlled study. After baseline assessments of salivation, swallowing, and motor and cognitive function, the participants were given DHM. The primary outcome was the difference in the Sialorrhea Clinical Scale for Parkinson's disease (SCS-PD) scores of salivation before and after treatment. The secondary outcomes included ≥ 30 % improvement in the SCS-PD score at each posttreatment visit and changes in the scores from other scales.ResultsA total of 39 participants were included in this study, and 4 participants dropped out. Finally, 35 patients completed all the visits. Salivation: After treatment for 1 week, the primary outcome, namely, the median SCS-PD score, decreased from 9.0 (IQR 5.0-12.0) at baseline to 7.0 (IQR 4.7-10.0) (P = 0.03). This effect persisted at 24 weeks, and the median score at 24 weeks was 5.0 (IQR 2.0-8.0) (P ConclusionDHM can significantly ameliorate salivation in PD patients over 24 weeks, with fewer adverse effects.

İlgili konular